ClinicalTrials.gg
CompletedNCT02388919ALTER0303Updated Sep 18, 2017

Study of Anlotinib in Patients With Advanced Non-small Cell Lung Cancer(ALTER0303)

A Phase 2/3 interventional study of Anlotinib and Placebo in Non-small Cell Lung Cancer, sponsored by Chia Tai Tianqing Pharmaceutical Group Co., Ltd.. Completed at 40 sites in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2017-09-18.

Sponsored by Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (part of Sino Biopharmaceutical Limited) · Phase 2/3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
439
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 73 studies testing anlotinib in Carcinoma, Non-Small-Cell Lung — 24 open to participants now, 27 under way, 1 of them phase 3. anlotinib · Carcinoma, Non-Small-Cell Lung.

Enrollment
2nd of 73
439 · median 51
Started
2015
the only one that year
Phase 2/3
3 of 73
1 open now
Registered
3rd of 73
by date
Lead sponsor
9 of 73
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Among the 73 studies testing anlotinib in Carcinoma, Non-Small-Cell Lung, this one is the 2nd largest by enrollment, is the only one that started in 2015, is one of 3 in phase 2/3, and was the 3rd registered.

Carcinoma, Non-Small-Cell Lung

7,628 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

24 of the 73 studies testing anlotinib in Carcinoma, Non-Small-Cell Lung are open now, in 1 country. Recruiting first, the newest first:

19 more — sign in →

By country, each count listing its studies:

All 24 open studies →

Where they have run

About anlotinib

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 1,325 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 224 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 73 studies testing anlotinib in Carcinoma, Non-Small-Cell Lung, or all of them as a file.
02

Study summary

Evaluate the efficacy and safety of Anlotinib as the 3-line treatment of patients with advanced non-small lung cancer, with placebo control.

Read the detailed description

Anlotinib (AL3818) is a kind of innovative medicines approved by State Food and Drug Administration(SFDA:2011L00661) which was researched by Jiangsu Chia-tai Tianqing Pharmaceutical Co., Ltd. Anlotinib is a kinase inhibitor of receptor tyrosine with multi-targets, especially for VEGFR1、VEGFR2、VEGFR3、FGFR1/2/3、PDGFRa/β c-Kit and MET.

03

Conditions studied

  • Non-small Cell Lung Cancer

Keywords

  • anlotinib
  • Cancer
  • NSCLC
  • Non-small Cell Lung Cancer
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Signed and dated
  2. Diagnosed with advanced NSCLC (phase IIIB/IV) through pathology, with measurable nidus(using 1.1)
  3. at least two systematic chemotherapy with upwards of 3-line treatments or cannot suffer
  4. Patients must provide detectable specimen (from tumor tissue or hydrothorax) before participating, who negative in EGFR\&ALK can participate or who positive in EGFR\&ALK, have or have not drug tolerance after the treatment with relative targeted drugs
  5. PS:0-1,Expected Survival Time: Over 3 months
  6. main organs function is normal
  7. The woman patients of childbearing age who must agree to take methods (e.g. intrauterine device, contraceptive pill or condom) during the research and within another 6 months after it; who are not in the lactation period and examined as negative in blood serum test or urine pregnancy test within 7 days before the research; The man patients who must agree to take contraceptive methods during the research and within another 6 months after it

Exclusion criteria

Exclusion Criteria:

  1. have used Anlotinib before
  2. Small Cell Lung Cancer (including small cell cancer and other kinds of cancer mixed with non-small cell cancer)
  3. examined as positive in EGFR\&ALK mutation detection and never take the treatment of TKIs
  4. central lung squamous carcinoma along with cavum, or non-small cell lung cancer along with hemoptysis (>50ml/day)
  5. other kinds of within 5 years or for now
  6. plan to take systemic anti-tumor therapy within 4 weeks before grouping or during the medicine-taking period of this research, including Cytotoxic Therapy, Signal Transduction Inhibitor, and Immunotherapy (or who use Mitomycin C within 6 weeks before taking the treatment with experimental drug); The patients who have already taken Extended Field Radiotherapy (EF-RT) within 4 weeks before grouping or Limited Field Radiotherapy with proposed assessment of nidus within 2 weeks before grouping
  7. have got non remissive toxic reactions derived from previous therapies, which is over level 1 in CTC AE (4.0), alopecia NOT included
  8. with kinds of factors which affect oral medicine (e.g. failing to swallow, gastrointestinal tract getting resected, chronic diarrhea and ileus)
  9. pleural effusion or ascites, resulting in respiratory syndrome (≥CTC AE level 2)
  10. symptoms of cannot be controlled and treated within less than 2 months
  11. get any severe diseases or the ones that cannot be controlled
  12. take major surgical treatments, open , or get overt traumatic injury within 28 days before grouping
  13. have any habitus or medical history of hemorrhage, however severe it is; the patients who have non healing wounds, ulcer or fracture after any events with hemorrhage or bleeding (≥ level 3)
  14. get arterial/venous thrombosis within 6 months, such as cerebrovascular accidents (including temporary ischemic stoke), deevenous thrombosis, and pulmonary embolism
  15. ever abuse psychiatric drugs and cannot abstain or who are diagnosed with mental disorder
  16. have participated in other clinical trials of anti-tumor medicine within 4 weeks
  17. diagnosed with disease which will severely endanger the security of patients or influence the completion of this research.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
439 participants (actual)

Study arms

  • Experimental
    Anlotinib

    Anlotinib p.o, qd and it should be continued until disease progress or toxicity cannot be tolerated or patients withdraw consent

    Drug: Anlotinib

  • Placebo comparator
    Placebo

    Placebo p.o, qd and it should be continued until disease progress or patients withdraw consent

    Drug: Placebo

Interventions

  • Basic dosage, take once when limosis in the morning. If patients cannot suffer from AEs, they can get declined dosage.

    Also known as: AL3818

  • DrugPlacebo

    Basic dosage, take once when limosis in the morning.

06

What researchers measure

Primary outcomes

  1. Overall Survival (OS)

    Time frame: From randomization until death (up to 24 months)

Secondary outcomes

  1. Progress free survival (PFS)

    Time frame: each 42 days up to PD or death(up to 24 months)

  2. Objective Response Rate (ORR)

    Time frame: each 42 days up to intolerance the toxicity or PD (up to 24 months)

  3. Disease Control Rate (DCR)

    Time frame: each 42 days up to intolerance the toxicity or PD (up to 24 months)

  4. Number of Participants with Adverse Events as a Measure of Safety and Tolerability

    Time frame: Until 30 day safety follow-up visit

07

Study locations

40 sites
  • Beijing Friendship Hospital, Capital Medical University
    Beijing, Beijing, China
  • Capital Medical University, Beijing Chest Hospital
    Beijing, Beijing, China
  • Chinese Academy of Medical Sciences Cancer Hospital
    Beijing, Beijing, China
  • Peking Union Medical College Hospital
    Beijing, Beijing, China
  • Chongqing Cancer Hospital
    Chongqing, Chongqing, China
  • Xinqiao Hospital
    Chongqing, Chongqing, China
  • Fujian Province Tumor Hospital
    Fuzhou, Fujian, China
  • Gansu Province Tumor Hospital
    Lanzhou, Gansu, China
  • Gansu Provincial People 's Hospital
    Lanzhou, Gansu, China
  • Lanzhou Military General Hospital
    Lanzhou, Gansu, China
  • First Affiliated Hospital of Guangzhou Medical University
    Guangzhou, Guangdong, China
  • First Affiliated Hospital of Shantou University Medical College
    Shantou, Guangdong, China
  • Fourth Hospital of Hebei Medical University
    Shijiazhuang, Hebei, China
  • Harbin medical university affiliated tumor hospita
    Harbin, Heilongjiang, China
  • Henan Province Tumor Hospital
    Luoyan, Henan, China
  • Hunan Province Tumor Hospital
    Changsha, Hunan, China
  • Xiangya Hospital Central South University
    Changsha, Hunan, China
  • Lianyungang First People 's Hospital
    Lianyungang, Jiangsu, China
  • Xuzhou Medical College Hospital
    Xuzhou, Jiangsu, China
  • Jiangxi Province Tumor Hospital
    Nanchang, Jiangxi, China
  • Second Affiliated Hospital of Nanchang University
    Nanchang, Jiangxi, China
  • Jilin Province Tumor Hospital
    Changchun, Jilin, China
  • Liaoning Provincial Tumor Hospital
    Shenyang, Liaoning, China
  • Qilu Hospital,Shandong University
    Jinan, Shandong, China
  • Shandong Province Tumor Hospital
    Jinan, Shandong, China
  • Linyi City Tumor Hospita
    Linyi, Shandong, China
  • Chest hospital affiliated to Shanghai jiaotong university
    Shanghai, Shanghai 200000, China
  • Cancer Hospital of Fudan University
    Shanghai, Shanghai, China
  • Shanghai Changhai Hospital
    Shanghai, Shanghai, China
  • Xinhua hospital affiliated to Shanghai jiaotong university
    Shanghai, Shanghai, China
  • First Affiliated Hospital of Xi'an Jiaotong University
    Xian, Shanxi, China
  • Tang Du Hospital
    Xian, Shanxi, China
  • West China Hospital , Sichuan University
    Chengdu, Sichuan, China
  • Sichuan Cancer Hospital
    Chongqing, Sichuan, China
  • 20th Floor, Block C, Lake Road, Hexi District, Tianjin Medical University Cancer Institute and Hospital .
    Tianjin, Tianjin 300600, China
  • Tianjin Medical University General Hospital
    Tianjin, Tianjin, China
  • Yunnan Province Tumor Hospital
    Kunming, Yunnan, China
  • The First Affiliated Hospital of Zhejiang University
    Hangzhou, Zhejiang, China
  • The Second Affiliated Hospital of Zhejiang University
    Hangzhou, Zhejiang, China
  • Zhejiang Province Tumor Hospital
    Hangzhou, Zhejiang, China
08

References and documents

Publications

  • Qin T, Liu Z, Wang J, Xia J, Liu S, Jia Y, Liu H, Li K. Anlotinib suppresses lymphangiogenesis and lymphatic metastasis in lung adenocarcinoma through a process potentially involving VEGFR-3 signaling. Cancer Biol Med. 2020 Aug 15;17(3):753-767. doi: 10.20892/j.issn.2095-3941.2020.0024. PubMed 32944404 ↗
  • Jiang S, Liang H, Liu Z, Zhao S, Liu J, Xie Z, Wang W, Zhang Y, Han B, He J, Liang W. The Impact of Anlotinib on Brain Metastases of Non-Small Cell Lung Cancer: Post Hoc Analysis of a Phase III Randomized Control Trial (ALTER0303). Oncologist. 2020 May;25(5):e870-e874. doi: 10.1634/theoncologist.2019-0838. Epub 2020 Feb 20. PubMed 32077550 ↗
  • Zhang PL, Liu ZJ. Esophago-tracheobronchial fistula following treatment of anlotinib in advanced squamous cell lung cancer: Two case reports. Medicine (Baltimore). 2019 Nov;98(44):e17700. doi: 10.1097/MD.0000000000017700. PubMed 31689797 ↗
  • Si XY, Wang HP, Zhang XT, Wang MZ, Zhang L. [Efficacy and safety of anlotinib in 16 patients with advanced non-small cell lung cancer]. Zhonghua Nei Ke Za Zhi. 2018 Nov 1;57(11):830-834. doi: 10.3760/cma.j.issn.0578-1426.2018.11.007. Chinese. PubMed 30392239 ↗
  • Han B, Li K, Wang Q, Zhang L, Shi J, Wang Z, Cheng Y, He J, Shi Y, Zhao Y, Yu H, Zhao Y, Chen W, Luo Y, Wu L, Wang X, Pirker R, Nan K, Jin F, Dong J, Li B, Sun Y. Effect of Anlotinib as a Third-Line or Further Treatment on Overall Survival of Patients With Advanced Non-Small Cell Lung Cancer: The ALTER 0303 Phase 3 Randomized Clinical Trial. JAMA Oncol. 2018 Nov 1;4(11):1569-1575. doi: 10.1001/jamaoncol.2018.3039. Erratum In: JAMA Oncol. 2018 Nov 1;4(11):1625. doi: 10.1001/jamaoncol.2018.5345. PubMed 30098152 ↗
  • Si X, Zhang L, Wang H, Zhang X, Wang M, Han B, Li K, Wang Q, Shi J, Wang Z, Cheng Y, He J, Shi Y, Chen W, Wang X, Luo Y, Nan K, Jin F, Li B, Chen Y, Zhou J, Wang D. Quality of life results from a randomized, double-blinded, placebo-controlled, multi-center phase III trial of anlotinib in patients with advanced non-small cell lung cancer. Lung Cancer. 2018 Aug;122:32-37. doi: 10.1016/j.lungcan.2018.05.013. Epub 2018 May 18. PubMed 30032842 ↗

Individual participant data

Plan to share: Undecided

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2015 to primary completion in Jan 2017, 22 months.

Of 56 phase 2/3 interventional studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 53 months of starting (the median), counting those still running; a quarter within 40. This study's 22 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 25, 2015
First posted
Mar 17, 2015
StartActual
Feb 26, 2015
Primary completionActual
Jan 5, 2017
CompletionActual
Jan 6, 2017
Last update
Sep 18, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 18, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02388919
Responsible party
Sponsor
First posted
Mar 17, 2015
Start date
Feb 26, 2015
Primary completion
Jan 5, 2017
Completion
Jan 6, 2017
Last update
Sep 18, 2017

Study contacts

Baohui Han, professor
study director · Chest hospital affiliated to Shanghai jiaotong university
Kai Lee, professor
study director · Tianjin Medical University Cancer Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Anlotinib

Start the discussion